Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
To access this article, please choose from the options below
This was an investigator-initiated trial, and GlaxoSmithKline Pharmaceuticals had no direct or indirect involvement in the design of the trial, data collection, or preparation or submission of the manuscript. GlaxoSmithKline provided rosiglitazone and placebo for this trial and partly funded the trial. None of the authors have a personal conflict of interest with the manufacturer of any of the marketed thiazolidinediones. V.R. is a consultant to Astellas, Gilead, Pfizer, Sanofi-Aventis, and Trophos. T.P. is a consultant for and owns 15% of BioPredictive, a company that markets FibroTest and SteatoTest.
The members of the Liver Injury in Diabetes and Obesity (LIDO) Study Group are as follows: André Grimaldi, Philippe Giral, Eric Bruckert, Arnaud Basdevant, Karine Clement, Agnès Hartemann-Heurtier, Sophie Gombert, Francine Lamaison, Dominique Simon, Joseph Moussalli, Pascal Lebray, Christiane Coussieu, Djamila Messous, Françoise Imbert-Bismut, Yves Benhamou, Cecilia D'Arrondel, Carole Bernhardt, Isabelle Ravalet, Hôpital Pitié-Salpêtrière; Philippe Podevin, Hôpital Cochin; Christian Boitard, Etienne Larger, Hôpital Hotel-Dieu; Lawrence Serfaty, Chantal Housset, Jacqueline Capeau, Hôpital Saint Antoine, all in Paris, France..
PII: S0016-5085(08)00630-6
doi:10.1053/j.gastro.2008.03.078
© 2008 AGA Institute. Published by Elsevier Inc. All rights reserved.

